NexImmune Inc. is pioneering advancements in the field of antigen-directed immunotherapies, focusing on harnessing the body's immune system to combat various diseases. The company has developed a proprietary technology known as Artificial Immune Modulation (AIM), which utilizes nanoparticles to mimic the function of dendritic cells—key players in the immune response. These AIM nanoparticles are designed to deliver precise instructions to T cells, the immune system's "foot soldiers," enabling them to either intensify their response against cancer and infectious diseases or dampen their activity in cases of autoimmune disorders. This innovative approach aims to restore effective immune function by addressing the dysfunction often seen in dendritic cells during disease progression.

NexImmune's clinical pipeline includes both injectable and adoptive cell therapy modalities. The AIM INJ technology allows for direct injection of nanoparticles to engage T cells within the body, streamlining the administration process and reducing manufacturing complexity. Meanwhile, the AIM ACT technology focuses on adoptive cell therapies, with ongoing clinical trials for treatments targeting relapsed acute myeloid leukemia and multiple myeloma. By leveraging their unique nanotechnology platform, NexImmune is committed to developing immunotherapies that not only improve patient outcomes but also offer potential curative solutions across a range of life-threatening conditions.

United States

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.

Cancer

Immune System Diseases

Infectious Diseases

NexImmune Inc

Acute myeloid leukemia

Myelodysplastic syndrome

NEXI-001 products contain populations of CD8+ T cells directed &nbsp;against HLA 02.01-restricted peptides from the WT1, PRAME and Cyclin A1 &nbsp;antigens, each of which is commonly over-expressed on AML blasts and &nbsp;leukemic stem cells. Each NEXI-001 product is composed of T cell memory &nbsp;subtypes that combine anti-tumor potency with long-term persistence. Of &nbsp;significance to this Phase 1/2 trial, each patient-specific experimental &nbsp;cell therapy product also contains very low proportions of T cell &nbsp;subtypes with potential to cause GvHD-related toxicities.
<a href="https://ir.neximmune.com/news-releases/news-release-details/preliminary-results-neximmunes-phase-12-trial-nexi-001-aml">Source</a>

NEXI-001 

Multiple myeloma

The AIM technology is &nbsp;designed to generate a targeted T cell-mediated immune response and is &nbsp;initially being developed as a cell therapy for the treatment of &nbsp;hematologic cancers. AIM nano-particles (AIM-np) act as synthetic &nbsp;dendritic cells to deliver immune-specific signals to targeted T cells &nbsp;and can direct the activation or suppression of cell-mediated immunity. &nbsp;In cancer, AIM-expanded T cells have demonstrated best-in-class &nbsp;anti-tumor properties as determined by in vitro analysis, including the &nbsp;ability to address key mechanisms of tumor escape and relapse through a &nbsp;unique combination of anti-tumor potency, multi-antigen target-specific &nbsp;killing, and long-term T cell persistence. The modular design of the AIM &nbsp;platform enables rapid expansion across multiple therapeutic areas &nbsp;(such as autoimmune diseases and infectious diseases), with both cell &nbsp;therapy and injectable products.
<a href="https://ir.neximmune.com/news-releases/news-release-details/first-patient-dosed-neximmune-phase-12-clinical-trial-nexi-002">Source</a>

NexImmune Inc

Company Details